Divis Labs Visakhapatnam Unit-2 has successful FDA inspection

Drug firm Divis Laboratories today said the US health regulator has conducted a successful inspection of its Unit-2 facility at Visakhapatnam this month.
"The company has had a successful inspection by the United States Food and Drug Administration (USFDA) for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February, 2016 with no observations," Divis Laboratories said in a filing to BSE.
Shares of Divis Laboratories today closed at Rs 993.90 on BSE, up 1.91 per cent from the previous close.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Feb 19 2016 | 4:57 PM IST
